<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05087693</url>
  </required_header>
  <id_info>
    <org_study_id>H21-01080</org_study_id>
    <nct_id>NCT05087693</nct_id>
  </id_info>
  <brief_title>Salbutamol Use in Ozone Air Pollution by People With Asthma and/or Exercise Induced Bronchoconstriction (EIB)</brief_title>
  <official_title>Examining the Effect of Salbutamol Use in Asthma and/or Exercise Induced Bronchoconstriction Whilst Exercising in Ozone Air Pollution</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of British Columbia</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of British Columbia</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Salbutamol use is increased in areas with high levels of ozone pollution and the potential&#xD;
      consequences of this are not well known. The purpose of this study is to examine the effect&#xD;
      of salbutamol on lung function and inflammation in people with asthma and/or EIB exercising&#xD;
      in ozone air pollution. To examine this, we are planning a randomized cross over trial where&#xD;
      people with asthma and/or EIB complete sub maximal exercise in four conditions on four&#xD;
      separate days. The four condition are: ozone + salbutamol, filtered air + salbutamol, ozone +&#xD;
      placebo medication, and filtered air + placebo medication.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">November 2021</start_date>
  <completion_date type="Anticipated">June 2022</completion_date>
  <primary_completion_date type="Anticipated">May 2022</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
    <masking_description>Drug condition (placebo or salbutamol) will be double blinded Air quality condition (ozone or filtered air) will be single blinded</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Change in Fraction of exhaled nitric oxide (FeNO) from baseline to 30 minutes after exercise</measure>
    <time_frame>Measured before and 30 minutes after exercise in each condition</time_frame>
    <description>Biomarker for airway inflammation</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in FEV1 from baseline to 30 minutes after exercise</measure>
    <time_frame>Measured before and 30 minutes after exercise in each condition</time_frame>
    <description>Measure of pulmonary function</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in FVC from baseline to 30 minutes after exercise</measure>
    <time_frame>Measured before and 30 minutes after exercise in each condition</time_frame>
    <description>Measure of pulmonary function</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in FEF25-75 from baseline to 30 minutes after exercise</measure>
    <time_frame>Measured before and 30 minutes after exercise in each condition</time_frame>
    <description>Measure of pulmonary function</description>
  </primary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Asthma and/or Exercise Induced Bronchoconstriction</condition>
  <condition>Ozone Air Pollution</condition>
  <arm_group>
    <arm_group_label>Exercising in ozone following salbutamol inhalation</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will be doing sub-maximal exercise (60% of VO2max for 30 minutes) on a cycle ergometer while inhaling 170ppb ozone after inhaling 200ug of salbutamol.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Exercising in filtered air following salbutamol inhalation</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Participants will be doing sub-maximal exercise (60% of VO2max for 30 minutes) on a cycle ergometer while inhaling filtered air after inhaling 200ug of salbutamol.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Exercising in ozone following placebo inhalation</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Participants will be doing sub-maximal exercise (60% of VO2max for 30 minutes) on a cycle ergometer while inhaling 170ppb ozone after inhaling placebo medication.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Exercising in filtered air following placebo inhalation</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Participants will be doing sub-maximal exercise (60% of VO2max for 30 minutes) on a cycle ergometer while inhaling filtered after inhaling placebo medication.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Salbutamol</intervention_name>
    <description>Inhaling 200ug of salbutamol</description>
    <arm_group_label>Exercising in filtered air following salbutamol inhalation</arm_group_label>
    <arm_group_label>Exercising in ozone following salbutamol inhalation</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo medication</intervention_name>
    <description>Inhaling placebo medication</description>
    <arm_group_label>Exercising in filtered air following placebo inhalation</arm_group_label>
    <arm_group_label>Exercising in ozone following placebo inhalation</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Ozone</intervention_name>
    <description>Breathing 170ppb ozone</description>
    <arm_group_label>Exercising in ozone following placebo inhalation</arm_group_label>
    <arm_group_label>Exercising in ozone following salbutamol inhalation</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Filtered Air</intervention_name>
    <description>Breathing filtered air</description>
    <arm_group_label>Exercising in filtered air following placebo inhalation</arm_group_label>
    <arm_group_label>Exercising in filtered air following salbutamol inhalation</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Exercise</intervention_name>
    <description>Cycling at 60% of VO2max on a cycle ergometer</description>
    <arm_group_label>Exercising in filtered air following placebo inhalation</arm_group_label>
    <arm_group_label>Exercising in filtered air following salbutamol inhalation</arm_group_label>
    <arm_group_label>Exercising in ozone following placebo inhalation</arm_group_label>
    <arm_group_label>Exercising in ozone following salbutamol inhalation</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Have asthma and/or EIB&#xD;
&#xD;
          -  Able to perform maximal exercise&#xD;
&#xD;
          -  Able to communicate sufficiently using the English language&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Allergic to salbutamol (also known as Ventolin)&#xD;
&#xD;
          -  Pregnant or potentially pregnant&#xD;
&#xD;
          -  Have a history of smoking&#xD;
&#xD;
          -  Had an upper respiratory tract infection within the last 4 weeks&#xD;
&#xD;
          -  Have a chronic respiratory disease other than asthma or EIB&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Ben Stothers, BKIN</last_name>
    <phone>604 240 7188</phone>
    <email>bennettstothers@gmail.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Environmental Physiology Laboratory</name>
      <address>
        <city>Vancouver</city>
        <state>British Columbia</state>
        <zip>V6T 1Z1</zip>
        <country>Canada</country>
      </address>
    </facility>
    <contact>
      <last_name>Michael Koehle, MD, PhD</last_name>
      <phone>604 788 7268</phone>
      <email>michael.koehle@ubc.ca</email>
    </contact>
    <investigator>
      <last_name>Michael Koehle, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>September 28, 2021</study_first_submitted>
  <study_first_submitted_qc>October 8, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">October 21, 2021</study_first_posted>
  <last_update_submitted>October 8, 2021</last_update_submitted>
  <last_update_submitted_qc>October 8, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 21, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of British Columbia</investigator_affiliation>
    <investigator_full_name>Michael Koehle</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <keyword>Asthma</keyword>
  <keyword>Exercise Induced Bronchoconstriction</keyword>
  <keyword>Salbutamol</keyword>
  <keyword>Ozone</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Asthma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Albuterol</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>Any data shared will not contain any personal identifiers.</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

